fenofibrate has been researched along with alpha-Lipoprotein Deficiency Disease, Familial in 4 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fenofibrate treatment partially reverses dyslipidemia in these subjects." | 1.43 | Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. ( Ginsberg, H; He, Y; Heinecke, JW; Oda, M; Reyes-Soffer, G; Ronsein, GE, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vazzana, N | 1 |
| Ganci, A | 1 |
| Cefalù, AB | 1 |
| Lattanzio, S | 1 |
| Noto, D | 1 |
| Santoro, N | 1 |
| Saggini, R | 1 |
| Puccetti, L | 1 |
| Averna, M | 1 |
| Davì, G | 1 |
| Hellerstein, M | 1 |
| Turner, S | 1 |
| Ronsein, GE | 1 |
| Reyes-Soffer, G | 1 |
| He, Y | 1 |
| Oda, M | 1 |
| Ginsberg, H | 1 |
| Heinecke, JW | 1 |
| Chang, CN | 1 |
| How, CH | 1 |
| Tavintharan, S | 1 |
1 review available for fenofibrate and alpha-Lipoprotein Deficiency Disease, Familial
| Article | Year |
|---|---|
Reverse cholesterol transport fluxes.
Topics: Arthritis, Rheumatoid; Azetidines; Biological Transport; Cholesterol; Ezetimibe; Fenofibrate; Humans | 2014 |
3 other studies available for fenofibrate and alpha-Lipoprotein Deficiency Disease, Familial
| Article | Year |
|---|---|
Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype.
Topics: Aged; Arachidonic Acids; Case-Control Studies; Cholesterol, HDL; Coronary Disease; Cross-Sectional S | 2013 |
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.
Topics: Aged; Apolipoprotein C-II; Aryldialkylphosphatase; Cardiovascular Diseases; Case-Control Studies; Di | 2016 |
Beyond low-density lipoprotein cholesterol: why, who and when.
Topics: Coronary Disease; Drug Therapy, Combination; Exercise; Fenofibrate; Humans; Hypertriglyceridemia; Hy | 2012 |